- Home
- SNAL vs PRLD Comparison
SNAL vs PRLD Comparison
Compare SNAL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- PRLD
- Stock Information
- Founded
- SNAL 2000
- PRLD 2016
- Country
- SNAL United States
- PRLD United States
- Employees
- SNAL N/A
- PRLD N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- SNAL Technology
- PRLD Health Care
- Exchange
- SNAL Nasdaq
- PRLD Nasdaq
- Market Cap
- SNAL 51.0M
- PRLD 48.6M
- IPO Year
- SNAL 2022
- PRLD 2020
- Fundamental
- Price
- SNAL $1.25
- PRLD $0.93
- Analyst Decision
- SNAL
- PRLD Strong Buy
- Analyst Count
- SNAL 0
- PRLD 2
- Target Price
- SNAL N/A
- PRLD $4.50
- AVG Volume (30 Days)
- SNAL 245.2K
- PRLD 181.0K
- Earning Date
- SNAL 08-12-2025
- PRLD 08-11-2025
- Dividend Yield
- SNAL N/A
- PRLD N/A
- EPS Growth
- SNAL N/A
- PRLD N/A
- EPS
- SNAL 0.04
- PRLD N/A
- Revenue
- SNAL $90,462,190.00
- PRLD $7,000,000.00
- Revenue This Year
- SNAL $24.50
- PRLD N/A
- Revenue Next Year
- SNAL $20.27
- PRLD N/A
- P/E Ratio
- SNAL $33.24
- PRLD N/A
- Revenue Growth
- SNAL 46.95
- PRLD N/A
- 52 Week Low
- SNAL $0.52
- PRLD $0.61
- 52 Week High
- SNAL $3.42
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- SNAL 41.84
- PRLD 59.77
- Support Level
- SNAL $1.30
- PRLD $0.77
- Resistance Level
- SNAL $1.55
- PRLD $0.85
- Average True Range (ATR)
- SNAL 0.18
- PRLD 0.07
- MACD
- SNAL -0.04
- PRLD 0.01
- Stochastic Oscillator
- SNAL 3.74
- PRLD 64.00
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.